Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and inventor of Acepodia’s core technology. Acepodia is a privately held biotechnology company focused on developing novel, targeted, allogeneic cell therapies to treat cancers.
Acepodia is pioneering next-generation technologies that effectively fight cancers. The company is developing first-in-class, off-the-shelf allogeneic cell therapies with significantly improved potency, better safety and broad applicability across hematologic and solid tumor cancers.
Acepodia is employing a flexible therapeutic design that leverages cutting edge technologies to develop the next generation of off-the-shelf cell therapies by supercharging select oNK cells and gamma delta (γδ) T cells to target and engage cancer cells.
Our approach is based on developing the most potent immune cell lines possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technologies, including Antibody-Cell-Conjugation (ACC) and chimeric antigen receptor (CAR), Acepodia believes it can fully realize the long-held promise of cell therapies in oncology.